- Home
- PINE vs LUNG Comparison
PINE vs LUNG Comparison
Compare PINE & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PINE | LUNG |
|---|---|---|
| Founded | 2019 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Industrial Specialties |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.6M | 63.6M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PINE | LUNG |
|---|---|---|
| Price | $16.31 | $2.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $17.67 | $6.81 |
| AVG Volume (30 Days) | 206.9K | ★ 1.0M |
| Earning Date | 02-05-2026 | 11-12-2025 |
| Dividend Yield | ★ 6.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $57,423,000.00 | ★ $91,664,000.00 |
| Revenue This Year | $14.13 | $9.21 |
| Revenue Next Year | $2.05 | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 14.81 | ★ 15.59 |
| 52 Week Low | $13.10 | $1.31 |
| 52 Week High | $17.88 | $9.37 |
Technical Indicators
Market Signals| Indicator | PINE | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 44.80 | 54.78 |
| Support Level | $16.41 | $2.16 |
| Resistance Level | $16.89 | $2.65 |
| Average True Range (ATR) | 0.38 | 0.20 |
| MACD | -0.19 | -0.02 |
| Stochastic Oscillator | 8.48 | 45.71 |
Price Performance
Historical ComparisonAbout PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.